Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1 1

Status

Completed 4Terminated 1

Sponsor Class

OTHER 65NIH 20NETWORK 5INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Multiple Myeloma 11Neuroblastoma 7Lymphoma 7Neoplasms, Plasma Cell 5Immunoglobulin Light-chain Amyloidosis 5Hodgkin Disease 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Biphenotypic, Acute 3Leukemia 3Ganglioneuroblastoma 3Waldenstrom Macroglobulinemia 2Sarcoma, Ewing 2Preleukemia 2Precancerous Conditions 2Neoplasms by Histologic Type 2Neoplasms 2Lymphoproliferative Disorders 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphatic Diseases 2Leukemia, Myeloid 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphoid 2Leukemia, B-Cell 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Diseases 2

Interventions

Melphalan 5Dexamethasone 5Prednisone 4Peripheral Blood Stem Cell Transplantation 3Doxorubicin 3Vincristine 2Thalidomide 2Lenalidomide 2Filgrastim 2Cyclophosphamide 2valspodar 1sargramostim 1fludarabine phosphate 1Vancomycin 1Tazobactam 1Reverse Transcriptase Polymerase Chain Reaction 1Radiotherapy 1Platelet Aggregation 1Piperacillin, Tazobactam Drug Combination 1Piperacillin 1Moxifloxacin 1Morphine 1Methotrexate 1Interferon-alpha 1In Situ Hybridization, Fluorescence 1Immunoenzyme Techniques 1Gene Expression Profiling 1Fenretinide 1Etoposide 1Dextromethorphan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
NETWORK × Neoplasms, Plasma Cell × Melphalan × Clear all
NCT00305812 2023-08-04

Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma

Canadian Cancer Trials Group

Phase 2 Completed
51 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00003353 2023-06-22

High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis

Eastern Cooperative Oncology Group

Phase 2 Completed
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00014508 2023-06-22

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Eastern Cooperative Oncology Group

Phase 2 Completed
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00052884 2023-06-18

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Eastern Cooperative Oncology Group

Phase 1 Terminated
8 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell, Drug-Related Side Effects and Adverse Reactions

NCT00002678 2020-04-02

Combination Chemotherapy in Treating Patients With Multiple Myeloma

Canadian Cancer Trials Group

Phase 3 Completed
595 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡